Dormant
AKTS · Aktis Oncology, Inc.
Last analysed ·
Against its published line
Nothing is through its line on this close.
How to read this
The red mark is the published kill line — the price that would prove the pick wrong. The dot is where the name closed on 28 August 2026; a dot LEFT of the mark has closed through its line.
Distance is drawn on a square-root scale, so close calls get the room. Past 8% a row stops competing and reads well clear, with a hollow dot to say the figure is off the drawn scale. Rows run tightest first.
Current thesis
Aktis Oncology's radiopharmaceutical story needs September conference attention to restore the August breakout. A weekly close above the 2026-08-28 close of $25.78 would confirm recovery, while a weekly close below $22 would invalidate the case.
Kill line
A weekly close below $22 invalidates the recovery thesis beneath the 2026-07-30 low of $22.39; a company-announced delay of NECTINIUM-2 preliminary data beyond Q1 2027 would separately break the development timetable.
Pick status
Open commitment catalyst 4d agoscored if the kill line above fires How this is scored →Latest analysis and events for AKTS —
As of 13 September 2026, the latest FrontierPicks analysis for Aktis Oncology, Inc. (AKTS): Aktis Oncology's radiopharmaceutical story needs September conference attention to restore the August breakout. A weekly close above the 2026-08-28 close of $25.78 would confirm recovery, while a weekly close below $22 would invalidate the case.
Kill line: A weekly close below $22 invalidates the recovery thesis beneath the 2026-07-30 low of $22.39; a company-announced delay of NECTINIUM-2 preliminary data beyond Q1 2027 would separately break the development timetable.
Most recent dated event on file: — catalyst 4d ago.
Current Thesis
Aktis Oncology's radiopharmaceutical story needs September conference attention to restore the August breakout; a weekly close above $25.78 would confirm recovery, while a weekly close below $22 would invalidate the case.
The change since the August update is broader analyst attention alongside weaker price structure. Oppenheimer initiated Outperform with a $40 analyst price target on 2026-09-09, but the supplied adjusted daily series closed at $23.30 on 2026-09-11, below the $25.78 close on 2026-08-28. The initiation is measured coverage activity; sustained demand cannot be inferred from it. Oppenheimer initiation
The narrative is maturing — Oppenheimer's 2026-09-09 initiation extends the August coverage cluster, while the 2026-09-11 close has surrendered the previously cleared $24 shelf. This is an inference about attention and price response, not evidence of clinical failure. The short interval since the initiation is too small to establish a repeatable analyst-response pattern.
Bullish and bearish views on Aktis Oncology, Inc.
The model's bull view on Aktis Oncology, Inc. (AKTS), in brief: Another analyst endorses the platform. Oppenheimer's 2026-09-09 initiation cited Aktis's miniprotein platform and clinical candidates AKY-1189 and AKY-2519. Its $40 analyst target expresses Oppenheimer's valuation view; confirmation of the recovery case requires a weekly close… The bear view: The August breakout has reversed. The supplied adjusted series places the 2026-09-11 close of $23.30 below the 2026-08-21 close of $24.07 and the 2026-08-28 close of $25.78. A weekly recovery above $25.78 would overturn this interpretation of failed follow-through. Clinical… Both cases follow in full.
Bull Case
- Another analyst endorses the platform. Oppenheimer's 2026-09-09 initiation cited Aktis's miniprotein platform and clinical candidates AKY-1189 and AKY-2519. Its $40 analyst target expresses Oppenheimer's valuation view; confirmation of the recovery case requires a weekly close above the market's 2026-08-28 close of $25.78. Initiation report
- Funding extends beyond planned data. Aktis reported $517.3 million in cash, cash equivalents and marketable securities at 2026-06-30 and projected funding into 2029 in its 2026-08-13 release. That supports the planned development window conditionally; withdrawal of that runway guidance would weaken the argument. Second-quarter results
Bear Case
- The August breakout has reversed. The supplied adjusted series places the 2026-09-11 close of $23.30 below the 2026-08-21 close of $24.07 and the 2026-08-28 close of $25.78. A weekly recovery above $25.78 would overturn this interpretation of failed follow-through.
- Clinical confirmation remains deferred. Aktis's 2026-08-13 release scheduled preliminary NECTINIUM-2 data for the first quarter of 2027. The conference announcement dated 2026-09-09 does not announce an efficacy readout; an earlier company-announced clinical result would change that evidence gap. Development timetable, conference announcement
Setup & Price Structure
The measured 2026-09-11 close is $23.30, with a three-month price increase of 6.2% and a 14-period relative strength index (RSI) of 45.8. The supplied adjusted series records a 2026-07-30 low of $22.39; the published $22 weekly-close threshold remains below that historical low. Neither a moving-average value nor current volume participation is supplied, so extension above a rising average and widening participation cannot be assessed.
The observable attention cluster consists of Wedbush and BMO initiations reported on 2026-08-19 and Oppenheimer's initiation on 2026-09-09. These are analyst publications, not measurements of retail ownership or short positioning. July Form 4 coverage identified insider sales on 2026-07-08 and 2026-07-20; those historical disclosures do not establish September selling. Dated analyst actions
Catalyst Calendar (next 30 days)
Both dates are company-confirmed. September conference schedule
Elapsed catalysts
- 2026-09-16 — Morgan Stanley healthcare conference. Aktis announced management participation at 8:30 a.m. Eastern Time and a webcast in its 2026-09-09 release. The presentation provides a dated opportunity to check development guidance; the recovery thesis still requires price confirmation. (passed 4d ago)
- 2026-09-17 — Oppenheimer radiopharmaceutical summit. Management participation was confirmed in the same 2026-09-09 announcement. The event follows Oppenheimer's initiation, making it a test of whether renewed attention accompanies recovery above the August close; attendance alone does not establish that outcome. (passed 3d ago)
What Would Change Our Mind
Loss of the July range would break the recovery thesis: a weekly close below $22 would breach the published threshold beneath the 2026-07-30 low of $22.39. Conversely, a weekly close above the 2026-08-28 close of $25.78 before that breach would satisfy the defined price-recovery case. Neither outcome establishes therapeutic efficacy.
A company disclosure delaying NECTINIUM-2 preliminary data beyond the first quarter of 2027 would separately invalidate the development timetable reaffirmed on 2026-08-13. Company milestone guidance
Correlation Notes
This is a single-company recovery case; no measured peer-return correlation is available in the supplied 2026-09-11 market snapshot. Aktis's 2026-09-09 announcement identifies a discovery collaboration with Eli Lilly outside Aktis's proprietary pipeline, establishing a business connection but no measured stock-price relationship. Lilly or radiopharmaceutical-sector headlines alone cannot confirm the defined recovery condition. Company description
Notes
- Ticker disambiguation: AKTS = Aktis Oncology (radiopharma, IPO January 2026), not the defunct Akoustis Technologies. A semiconductor theme tag on this ticker is a data error.
- Pre-revenue apart from Lilly collaboration revenue recognised cost-incurred. No clinical efficacy data until Q1 2027 (AKY-1189 NECTINIUM-2 Phase 1b preliminary).
- Eli Lilly holds a $100M IPO anchor stake plus a collaboration worth up to $1.1B; Lilly radiopharma headlines read through to AKTS.
- The ~180-day IPO lock-up (est. ~2026-07-07 to 07-11) is elapsed; Form 4 flow is a continuing supply variable rather than a single-day event.
- Cash and marketable securities $517.3M at 2026-06-30, guided to fund the operating plan into 2029 — no scheduled dilution event before the 2027 readouts.
- Screener consensus lags the primary notes: aggregator pages showed $31.50 across two analysts on 2026-08-30 while five houses publish $33-$40.
Related · shared themes
APGE
Apogee Therapeutics, Inc.
Apogee Therapeutics’ $135.11-per-share cash-acquisition thesis resolved with AbbVie’s completion on 2026-09-03. The 2026-09-14 Form 15 advances administrative closure, leaving no unresolved APGE acquisition catalyst.
ATAI
AtaiBeckley Inc.
AtaiBeckley's Lilly acquisition thesis resolved with completion on 2026-09-11, ending the pending-merger case. Remaining contingent payments depend on disclosed clinical and regulatory milestones; Nasdaq suspended ATAI effective 2026-09-14.
PSNL
Personalis, Inc.
The MRD story has been overtaken by a live sale process: StreetInsider reported 2026-07-17 that Personalis retained Centerview, TD Securities and Cooley after takeover interest from Merck (already a >10% holder and 19% of Q1 revenue) plus two other suitors. Price broke to a $16.39 52-week high; Needham $17 and TD Cowen $18 now sit above the tape. Aug-4 Q2 is the next hard date.
RVMD
Revolution Medicines, Inc.
Regulatory-clock narrative re-accelerating: the rolling NDA under the FDA National Priority Voucher is "nearing completion" (2026-07-07) and the EMA opened a phased CHMP review the same day, while the Street ceiling walked from ~$186 to $235 (Guggenheim, 2026-07-09). The three-week digestion off the $192.62 high resolved higher on 2026-07-17 (+3.9% to $186.16) — the breakout retest the prior note wanted.
See also · stocks to watch